Therefore, we hypothesized RAS being the key downstream regulator of EGFR which in turn might govern the expression of EXO1. In order to investigate this association, we took a KRAS mutant breast cancer cell line, MDA-MB-231 and treated with RAS inhibitor, salirasib. Here, EGFR is linked to breast cancer.